1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…
REGULATORY
Think Tanks Propose New Pricing Methods for Innovative Meds, Multi-Faceted Evaluations
Three independent organizations including think tanks proposed new drug pricing methods to appropriately evaluate innovation at a health ministry panel hearing on October 27, with one representative stressing the need to break the impasse in deliberations to create a system…
To read the full story
Related Article
- Deloitte Proposal to Shed Number of Generics Aims to Spur Industry Consolidation
December 5, 2022
- Deloitte Proposes Pricing Schemes to Encourage Consolidation of Generic Makers
October 31, 2022
- Ex-Bureaucrats, Academics Trade Barbs over Macroeconomic Indexing; Will MOF Allow Rise in Drug Cost?
October 28, 2022
REGULATORY
- Ishiba Vows to Take Steps on OTC-Like Meds from FY2026, Freeze Certain Hikes in Copay Caps
February 19, 2025
- Japan Cabinet OKs 5-Year Healthcare Strategy from FY2025
February 19, 2025
- Minister Touts “Balanced” Off-Year Revision after USCC Letter
February 19, 2025
- Espha’s Januvia Generic on Approval Roster towards June Listing
February 18, 2025
- “Annual Reports” Allowed for CMC Changes with Minimal Impact: MHLW
February 17, 2025
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…